Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Releases Quarterly Earnings Results

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) released its quarterly earnings results on Wednesday. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.32), FiscalAI reports. The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.38 million.

Armata Pharmaceuticals Stock Performance

ARMP traded down $0.06 during trading on Wednesday, hitting $6.69. The stock had a trading volume of 106,489 shares, compared to its average volume of 152,750. The stock has a 50 day simple moving average of $3.88 and a two-hundred day simple moving average of $2.73. Armata Pharmaceuticals has a twelve month low of $0.90 and a twelve month high of $16.34. The company has a market capitalization of $242.38 million, a PE ratio of -6.50 and a beta of 1.12.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.